Multibagger pharma penny stock under Rs 30 hit upper circuit after strategic Pan India distribution tie-up with Wockhardt Limited
DSIJ Intelligence-1 / 10 Sep 2025/ Categories: Multibaggers, Penny Stocks, Trending
The stock gave multibagger returns of 2,600 per cent in 3 years and a whopping 11,250 per cent in 5 years.
On Wednesday, shares of Shukra Pharmaceuticals Ltd were locked in a 2 per cent upper circuit to Rs 27.24 per share from its previous closing of Rs 26.71 per share. The stock’s 52-week high is Rs 28.92 per share while its 52-week low is Rs 5.75 per share.
Shukra Pharmaceuticals Limited has announced a new strategic distribution tie-up with Wockhardt Limited, a prominent global pharmaceutical company. This non-exclusive agreement, valid from September 9, 2025, to March 2026, authorises Shukra Pharmaceuticals to distribute and manage Wockhardt's products across all ESIC/ESIS and Defence Hospitals in India. The agreement allows Shukra Pharmaceuticals to quote products, collect orders and payments, and raise invoices on behalf of Wockhardt. The products covered under this agreement include advanced anti-infective formulations such as the breakthrough antibiotics EMROK® (Levonadifloxacin) and MIQNAF® (Nafithromycin), which are crucial for combating critical infections.
This partnership is a major milestone for Shukra Pharmaceuticals, as it significantly strengthens its presence within institutional and government healthcare networks across the country. The company anticipates that this collaboration will enhance its revenue and operational footprint, contributing to long-term value for shareholders. By aligning with India's expanding healthcare and hospital infrastructure, the company's management believes this development will have a positive and lasting impact on its financial and operational performance. The strategic tie-up with a respected name like Wockhardt is seen as a key step in Shukra Pharmaceuticals' growth journey.
DSIJ’s ‘Micro Marvel' service recommends micro-cap stocks with the potential to grow multifold in long run. If this interests you, do download the service details here.
About the Company
Established in 1993, Shukra Pharmaceuticals Ltd. operates in both manufacturing and trading pharmaceuticals, alongside offering laboratory testing services. The company has a market cap of over Rs 598.14 crore with a 3-year stock price CAGR of 190 per cent.
The company reported positive results in both quarterly and annual financial statements. In Q1FY26, the company reported net sales of Rs 5.39 crore and net profit of Rs 1.03 crore. In FY25, the company did net sales of Rs 32.59 crore and net profit of Rs 9.58 per share.
According to the shareholding, the promoters own a 50.95 per cent stake in the company while DIIs own 0.11 per cent and the public owns 48.94 per cent as of March 2025. The stock gave multibagger returns of 2,600 per cent in 3 years and a whopping 11,250 per cent in 5 years.
Disclaimer: The article is for informational purposes only and not investment advice.